- This week, we have registered two new major short calls.
- Hindenburg came out with its fourth campaign this year. As per usual, the heavy hitter delivered right from the start. Hindenburg alleged that the Polish company, LPP is dealing with Russia despite the war and sanctions. The shares are down as much as 37% on the first day of the report.
- Spruce Point targeted Enfusion, a tech company serving the financial sector, due to allegations of dubious revenue accounting and questionable corporate governance. The management team apparently has a poor track record, as some were involved with troubled entities that were charged by the SEC. The stock is flat for now.
- Lastly, we are tracking the most recent stock price gyrations at several previous targets. We focus on a failed EV play, a struggling solar business, and a rebounding AI stock which caught the interest of retailers.
Save time and ask us for independent short thesis verification. Get our custom support. Contact Breakout Point!
Bits and Pieces
- Muddy Waters launches long-only Vietnam fund (via PIO)
- Scorpion can record another win with its DNA campaign. The stock has reached their intended downside, but might go even further.
Interesting what $DNA originally projected, as it approaches penny stock status at all time lows. https://t.co/QmqA9yVATQ
— Scorpion Capital (@ScorpionFund) March 14, 2024
- The once battleground battery tech business is now down 63% since the activist first focused on it.
To their credit, $ENVX made things quite clear some time ago https://t.co/k7ERQ5m9Pw
— logphase research (@log_phase) March 13, 2024
- Supposed AI company is trying to beef up its financials, Wolfpack does not see much value. INOD is down 49% so far.
The only rational explanation we can see for offering to buy $APX, which earned itself a going concern warning from its auditor after losing Google as a client, is that it has ~$60m in NWC and ~$30m in cash. This looks to us like an attempted backdoor capital raise. Our analysis…
— Wolfpack Research (@WolfpackReports) March 12, 2024
- Viceroy is going to soon update their campaign against the Swedish lumber company. The stock is up 9% so far.
$SCA analysts assert the recent Munich RE purchase justify the valuation model.
— Viceroy (@viceroyresearch) March 12, 2024
It is a very different base, with c.50% higher growth rates on the Finnish deal + a mix of wind turbines/energy contracts. If anything, it justifies why Svenska Cellulosa is overvalued. Updates soon
- Culper sees over 20% drop in Acadia (ACAD) as the company fails drug test. The stock is down 26% for now.
Today, ACADIA Pharmaceuticals $ACAD disclosed that its Phase 3 trial for pimavanserin in NSS failed its primary endpoint. The Company doesn't plan to conduct any further trials. With Daybue unraveling, $ACAD doesn't have much left to stand on...
— Culper (@CulperResearch) March 11, 2024
Shares are down ~15% after hours.
- Another biotech win this week for Sumerian.
$AMLX Our initial short report thread from beginning of 2022. Finally proving no significant difference with placebo and failing to meet all secondary endpoints: https://t.co/2gMI6tvPs0
— Cici (@SumerianRsch) March 11, 2024
Big Movers
This week, we have seen plenty of stocks move in the right direction for the short-sellers. One of the biggest movers in the right direction was a campaign targeting Fisker (FSR), which plunged 57% in the past five days. It was Fuzzy Panda who targeted this EV play due to allegations of poor corporate governance.
Most importantly, the report believed the company has misled investors about its cash position. FSR apparently has large bank guarantees that it needs to maintain, which explains the large cash position. This means the company is likely to continue to fund its losses through ATM offerings which are going to hurt shareholder value and put the business at risk.
The thesis has now played out in its entirety. The stock is down 79% so far and the recent drop was due to speculations of a bankruptcy filing as the business is not performing. Fuzzy Panda is wondering whether they should cover or not.
Cover or don't cover a stock that is trading for <$0.20?
— FuzzyPanda (@FuzzyPandaShort) March 14, 2024
Asking for $FSR
Another significant win for the EV-focused activist.
Another stock that somewhat went in the right direction for short-sellers was Sunrun (RUN), which is down about 24% in the past five days. The solar business was targeted by Muddy Waters due to allegations of a dubious business model. However other activists such as Kynikos has also piled on and continued to monitor the situation.
Most importantly, Muddy's report believed the company could face a dire need for equity issuance to stay afloat. First, RUN is allegedly overestimating the value of their current assets due to the use of questionable accounting. Muddy adjusts 'Net Earnings Assets' down as much as 90%. Second, the company is apparently misleading IRS about its Power Purchase agreements. Third, RUN's ABS securitization could expose the holders to the bankruptcy of the company due to a lack of reserve.
RUN has been somewhat of a difficult campaign. The stock has a tendency to whipsaw against short-sellers as the market suddenly becomes interested in solar. Now that the tables have turned as the company continues to report troublesome numbers which support the initial thesis focus on an uneconomic business model. The stock is down 34% since the initial report. Moreover, the political climate is also not as friendly. While Muddy did not update their thesis, a couple of bears on Twitter shared their view amid the recent drop.
1/25 Question @MaryGPowell and $RUN regarding your ongoing use of a 6% discount rate to value your owned assets (the value of which you take a 30% tax credit on) a thread.
— Gordon Johnson (@GordonJohnson19) March 11, 2024
What happens when your residential solar company goes bankrupt. (It ain’t pretty) https://t.co/FjriNoUfZs
— Diogenes (@WallStCynic) March 14, 2024
On the other side of the tracks, we have seen several stocks go against the short-sellers. One of the biggest movers was Soundhound (SOUN), which jumped about 42% in the past five days. Most recently, this speech recognition company turned AI play has been targeted by Capybara Research due to allegations of a poor business model. Before that Culper raised similar allegations.
Most importantly, the report believed the company is using the recent AI boom to talk up its share price. The market recently pushed up SOUN due to the stake of NVDA in the company. However, that investment is not new; it came in 2017. The CEO used this to insinuate potential deals, while the reality apparently suggests no such interest, given SOUN's track record of burning over $500m in shareholder cash.
As with other Capybara campaigns, they are taking a position in heavy retail names, which tend to have the risk of completely going against them for some time. SOUN might be another one. Twitter traders and Redditors are all over the company despite it not reporting anything overly significant. They are chasing the gains, but it seems some already started to turn as the valuation does not make much sense.
SoundHound AI $SOUN has a market cap of $2.6 Billion, 2023 revenue of $45.87 mn, net loss of $89 mn, and book value of $28.17 mn. The company has been around since 2005.
— Kashyap Sriram (@kashyap286) March 13, 2024
This stock can collapse 99% and still be overvalued. It amazes me investors can chase stocks like this with… pic.twitter.com/uUoDmfdXFq
Capybara is saying the opportunity is ripe and an update is coming.
$SOUN has been pumped to provide another beautiful short opportunity. So, stay tuned for our full report coming soon https://t.co/sYCOSOwE7a
— Capybara Research (@CapybaraShort) March 14, 2024
SOUN investors should be aware of Capybara's track record. All other campaigns are successful, with all of the stocks down at least 50%.
Heavy Hitter Hindenburg
This week, we also saw the return of Hindenburg and what an impact they made right away. The activist targeted LPP, a $8.4bn fashion retailer based in Poland, due to allegations of fraudulent corporate governance.
Most importantly, the report believes the company's apparent effort to divest the Russian operations following the war in Ukraine was just a sham. LPP apparently finalized a transaction with a vague counterparty, but in reality, they continued to benefit from the Russian market. The entities involved in the transaction where LPP was selling the Russian assets are filled with significant red flags, such as the date of incorporation just one day before the transaction.
Far East Services was incorporated just one day before LPP announced it had reached an agreement to sell its Russian subsidiary.
— Hindenburg Research (@HindenburgRes) March 15, 2024
It has no externally verifiable presence, track record in the fashion industry, or apparent associations with China.
(13/x) pic.twitter.com/bBdQTk7CK1
Moreover, Hindenburg also went into the Russian stores and checked LPP items sold. They match the Polish offer, meaning that LPP still manages to get their inventory into the country. This is likely behind the 40% revenue growth that the company reported, without saying most of it comes from Russia.
The market has rewarded LPP’s reported 40.5% core revenue growth—virtually unheard of in the retail apparel industry—by sending the stock back toward all-time highs.
— Hindenburg Research (@HindenburgRes) March 15, 2024
(10/x) pic.twitter.com/QJUFb1F3HF
Due to all this, the short-seller sees a significant downside opportunity. The market is likely to eventually sell the shares as the company will likely face legal risk. The stock started to slide immediately and is down as much as 37%l.
The company scrambled to respond and came out with the classic denial of allegations, albeit with a twist. LPP definitely included a lot more language aimed at Hindenburg's international campaigns, such as Adani, and LPP likely tries to paint Hindenburg as an actor connected to international security agencies. Polish fintwit is mostly neutral, with some bears and bulls but no apparent strong reaction.
New Campaigns
Spruce Point : Enfusion (ENFN) - Up 0.1%
- The activist targeted this $1.2bn tech company due to allegations of dubious accounting and poor business model.
- Most importantly, the report believes the revenue accounting raises red flags. The company apparently quietly revised certain accounting without explaining much. The account receivables are also going down while revenue is increasing which allegedly does not make much sense. Spruce believes revenue overstatement risk is large.
- Moreover, ENFN's management supposedly has a tainted track record. The company had a significant turnaround at key C-level positions. The current CEO apparently served as Director of Risk management at an investment firm when the SEC decided to charge them with illegal trade scheme. The CFO was employed as CAO of General Electric during a time when the company settled with the SEC regarding its accounting.
- Due to all this, the short-seller sees up to 60% downside opportunity. The market is likely to eventually sell the shares as the company will have to clarify its accounting and potentially disappoint street expectations.
FAQ | Q: Can I publish parts of the above data and analytics in an article? A: As long as you reference our work - yes, you can.
FAQ | Q: Could you provide more related data and analytics? A: Sure, contact us, and we'll try to help as soon as possible.
* Note: Presented data and analytics is as of available on 2024-03-15 UTC 12:00.
The services and any information provided by Breakout Point or on the Breakout Point website shall not be or construed to be any advice, guidance or recommendation to take, or not to take, any actions or decisions in relation to any investment, divestment or the purchase or sale of any assets, shares, participations or any securities of any kind. Any information obtained through Breakout Point and its services should never be used as a substitute for financial or other professional advice. Any decisions based on, or taken by use of, information obtained through Breakout Point and by its services are entirely at own risk.